Mammographic screening only matters in the detectable preclinical period of breast cancer
In a recent issue of the Journal of Medical Screening, Fielder et al. found that the Breast Test Wales screening programme is achieving a reduction in breast cancer mortality of 25% in women attending for screening. 1 Mammographic screening in their case-control study was defined as 'ever attended routine screening', 'number of routine screens attended', and 'time since last screen'. We believe that cumulative measures of mammographic screening lack a biological justification. Instead, screening history should be limited to the period when the cancer is potentially detectable on the mammogramthat is, in the detectable preclinical period. 2,3 Only then can screening be effective in reducing the risk of breast cancer death.
The exact duration of the detectable preclinical period is not known, but will vary across age groups and will also vary for cases within age groups, depending mainly on the growth rate of breast cancer. 4 In a case-control study, screening history should therefore focus on the time period directly preceding diagnosis of the case and should probably not exceed four years. 5 A screening examination that took place 10 years ago, for instance, is thus not relevant. Screening has no memory and there is no biological mechanism through which this previous examination can still influence the chance of detection at screening. For the same reason, the cumulative number of routine screens attended in and of itself cannot influence the risk of dying from breast cancer. Therefore, our interest is in whether or not a screening examination took place shortly before diagnosis, not in the total number of screens.
Why then does Table 3 in the paper seem to suggest an inverse 'dose-response relation' between the number of screens attended and the risk of breast cancer death? As the authors report, the magnitude of the reduction in risk was approximately 35% in the first two screening examinations, increasing to roughly 60% for more than two screens. We expect that this association occurs mainly through a high correlation with 'time since last screen'. It is highly likely that women who have participated in (more than) three screens also participated in the most recent screening examination. The time between this screening examination and time of diagnosis will be short, thus decreasing the risk of dying from breast cancer. In this sense, the 'number of screens' seems to be no more than a proxy for a 'recent screening examination'.
Presenting cumulative measures on screening history as Fielder et al. do in Table 3 of their paper seems to suggest that a significant level of protection is conferred to a woman attending at least three screens in the programme. We want to stress that women in the target population can only achieve full benefit from mammographic screening when they are screened regularly, that is every two to three years. 
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Author response
We thank Dr Broeders and Verbeek for their letter. There is much to agree with in their comments. For example, the number of screens attended is indeed confounded with time since the last screen, but we would raise two reservations.
1. While it is true that the only screen that can confer a benefit is the one that takes place during the preclinical screen-detectable period, a woman offered screening does not know when this will be. The more screens she attends, the more likely it is that, in the unfortunate event of her developing breast cancer, a screen will take place during the preclinical screen-detectable period. There is an analogy with epidemiological research on sexually transmitted conditions, in which the number of partners is a factor frequently investigated. One could argue that the only sexual partner that matters is the one who transmits the infection. Again, the larger the number of sexual partners, the more likely it is that one will be infected. 2. We agree that full benefit is only achieved by regular attendance in the programme. However, the number of screens attended may be as good a measure of this as recent attendance.
Despite our second point above, we agree that attendance within a few years of diagnosis should have been presented. The odds ratio for risk of death from breast cancer in those attending for screening within the four years preceding diagnosis or pseudodiagnosis -the diagnosis date of the case to which the control is matched -relative to those who did not is 0.66 (95% confidence interval 0.48-0.89).
